I have similar opinion about the book. Almost finished Section 1. IMHO the beginning of the book was dull with two many statements and quotes but no case studies/data supporting those. So far I have liked Chapter 3 where author discusses biotech business with analogy from Peter Thiel’s book. This chapter actually discusses some case studies and business models. Based on my experience so far, I am keep my expectations low.
Yes, the book has very high PE 
| Subscribe To Our Free Newsletter |
